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To the Editor,
The widespread use of immunoassays can be attributed to 
their analytical sensitivity combined with the possibility 
of direct measurement in unprocessed serum or plasma 
samples. However, a complex matrix such as serum can 
challenge specificity or result in analytical interference 
[1]. Apart from interference due to hemolysis or lipemia, 
interference can occur due to compounds with a similar 
structure as the analyte or through the occurrence of 
human antibodies with affinity for immunoassay compo-
nents [2]. In the last case, assay setup and differences in 
assay sensitivity for interference can result in seemingly 
normal, falsely elevated or low analyte concentrations, 
resulting in the possibility of errors in diagnostic and 
therapeutical decisions. Identifying the origin and speci-
ficity of interference is in most cases not straightforward 
and often requires investment in laboratory resources. 
However, patient care will benefit when both the origin 
of interference and the extent to which the interference 
affects different assays is known.
We recently encountered a case in which inter-
ference in Roche hormone immunoassays suggested 
hyperthyroidism. A 40-year-old male visited his general 
practitioner with intestinal problems and joint pain. His 
general practitioner ordered thyroid-stimulating hormone 
(TSH) and free thyroxine (T4) analysis [free T4 29.8 pmol/L 
(reference interval 10–24 pmol/L); TSH 0.28 mU/L (refer-
ence interval 0.5–5 mU/L)]. Based on the biochemical 
parameters, antithyroid drug treatment was started (30 mg 
thiamazole daily). However, the biochemical manifesta-
tions of hyperthyroidism remained unchanged in the fol-
lowing month and the physical problems did not resolve 
on which the dosage of thiamazole was increased to 60 mg 
daily. As antithyroid drug treatment was still ineffective 
after 2 months, matrix interference in the TSH and free T4 
immunoassays was suspected and thiamazole treatment 
was discontinued. Additional blood analysis showed an 
elevated cortisol concentration of 877 nmol/L (reference 
interval 150–700 nmol/L) and a testosterone concentra-
tion of 37.6 nmol/L (reference interval 10–30 nmol/L) both 
measured in a blood sample drawn at 8 a.m.
To gain further insight into the extent of interference, 
additional hormones were measured using Roche immu-
noassays characterized by differences in assay setup and 
labeling of tracer and antibody (Table 1). Comparison with 
alternative assays suggested interference in the Roche T3 
and prolactin assays as well. We encountered complex 
results in the attempt to identify the origin of interference 
(Table 1). Firstly, a doubling dilutions test showed sus-
tained elevated cortisol concentrations. For testosterone, 
doubling dilutions gave a sustained elevated concentra-
tion in three out of the four dilutions. Adding 1/5 volume 
of mouse serum to control human male serum resulted in 
an expected reduction in testosterone concentration of 
20%. However, addition of mouse serum to our patient’s 
serum unexpectedly resulted in an increase of the already 
elevated testosterone concentration by 13%. Based on 
these results, an immunological origin of interference was 
suspected. To corroborate our hypothesis, we used heat 
treatment of serum (20 min at 55 °C or 60 °C) to dissociate 
immune complexes and thereby increasing free antibody 
concentration and possibly interference. This resulted 
in an increase of the already falsely elevated cortisol 
concentration by 75%. The falsely elevated testosterone 
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concentration increased with an additional 50%. Cortisol 
and testosterone molecules were heat-stable at the indi-
cated temperatures and incubation time. Using polyeth-
ylene glycol (PEG) precipitation [3] we tried to remove the 
interfering antibodies and immune complexes from solu-
tion. Spiking of samples with serum positive for thyroper-
oxidase antibodies was used as an internal control. With 
































Figure 1: Assay setup and proposed method of interference.
(A) Competitive assay setup with biotin labeled tracer. Amount of binding of tracer (in complex with ruthenium labeled antibody) to 
paramagnetic bead is inversely proportional to the analyte concentration. (B) Interaction of heterophilic antibody with biotin labeled 
tracer prevents binding to paramagnetic bead. (C) Competitive assay setup with biotin labeled antibody. (D) Interaction of heterophilic 
antibody with biotin labeled antibody prevents binding to paramagnetic bead. (E) Sandwich assay setup. (F) Interaction of heterophilic 
antibody with biotin labeled antibody-analyte-ruthenium complex prevents binding to paramagnetic bead. (G) Incubation of control 
serum with excess biotin results in binding of streptavidin on paramagnetic beads resulting in falsely elevated analyte concentrations. 
(H) Incubation of patient serum with excess biotin results in binding of streptavidin on paramagnetic beads. The heterophilic antibody 
forms a bridge between the paramagnetic bead bound biotin and biotin labeled tracer or antibody. This results in falsely lowered analyte 
concentrations.
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the pellet fraction of our patient increased to 75%–80%, 
which suggested that the interference was originating 
from large proteins or protein complexes. No cortisol could 
be recovered from the pellet fraction of control serum.
As interfering antibodies are mainly IgM class anti-
bodies [4], we incubated serum with antibodies directed 
against human IgM in an attempt to modulate the inter-
ference. This reduced the interference in the cortisol and 
testosterone assays but increased the interference in the 
free T4, T3, TSH and prolactin assays. This suggested that 
the interfering antibody might interact with assay com-
ponents other than assay antibodies. As such, the inter-
fering antibody would classify as a heterophilic antibody 
rather than a human anti-animal antibody. To clarify the 
specificity of the heterophilic IgM antibody we incubated 
serum from our patient with separate components of the 
Roche immunoassays for which interference by human 
antibodies has been demonstrated before [5–7]. The com-
petitive assays used are characterized by either a tracer 
(Figure 1A) or analyte specific antibody (Figure 1C) labeled 
with biotin, which allows binding to streptavidin-coated 
magnetic microparticles. Indirect analyte quantification 
is obtained through chemiluminescent emission from a 
ruthenium complex linked to either a tracer or analyte 
specific antibody. The sandwich methods are character-
ized by two assay specific antibodies labeled with either 
biotin or a ruthenium label (Figure 1E).
No effect on interference was noticed when serum was 
incubated with agarose-streptavidin resin, ruthenium chlo-
ride or the ruthenium label. Finally, we analyzed if the inter-
ference could originate from antibodies interacting with 
biotin. Addition of biotin (final concentration 70 μg/mL) 
resulted in an expected testosterone concentration above 
the measuring range in control male serum. Interestingly, 
addition of biotin to patient serum resulted in a testoster-
one concentration below the limit of detection. This sug-
gests the presence of a heterophilic IgM antibody which 
interacts with biotin. In competitive assays this would 
result in binding of the biotin labeled tracer (Figure 1B) 
or biotin labeled assay antibody (Figure 1D) resulting in 
elevated analyte concentrations. For the sandwich assay, 
interaction with the biotin labeled assay antibody would 
result in lowered analyte concentrations (Figure 1F). Addi-
tion of free biotin in the absence of interfering antibody 
blocks streptavidin binding to biotinylated assay com-
ponents resulting in elevated analyte concentrations 
for competitive assays (Figure 1G) while in the presence 
of interfering antibody a surplus of ruthenium labeled 
components can be bound and affect assay results in the 
opposite direction (Figure 1H).
Biotin supplements have previously been reported 
as a cause of low parathyroid hormone concentration 
as increased free serum biotin mimics the biotinylated 
antibody used in the detection process of the assay [8]. 
Also, intake of large biotin doses has been the cause of 
misdiagnosis of Graves’ disease [9]. As incubation of 
serum from our patient with agarose-streptavidin resin 
did not normalize the test results, interference due to 
elevated free biotin concentrations can be excluded. 
Therefore we conclude that the heterophilic antibody 
interacts with biotinylated assay components, resulting 
in varying analytical effects. Anti-biotin IgM antibodies 
were shown previously to occur in 3% of adults [10]. As 
biotinylation is widely applied in biochemical assays 
this could result in falsely lowered or increased analyte 
concentrations in a substantial amount of patients 
worldwide. Whether or not the interference will result 
in significant changes from the true analyte concentra-
tion depends on both antibody affinity for biotin and 
antibody concentration as well as on assay sensitivity 
for interference.
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